Table 2.
Adverse effect | Related medications | Treatment and management | Comments |
---|---|---|---|
Flu-like symptoms | Interferon Ribavirin |
Regular daily schedule Adequate sleep Hydration Exercise Acetaminophen |
May include fatigue, myalgias, weakness, fever, and insomnia. |
Anemia | Interferon Ribavirin Telaprevir Boceprevir Faldaprevir |
Ribavirin dose reduction Erythropoietin or other erythrocyte-stimulating agents Blood transfusions |
DAA association with anemia is greatest for boceprevir, telaprevir, and faldaprevir. |
Neutropenia | Interferon Ribavirin |
Interferon dose reduction Filgrastim |
Unclear clinical significance of neutropenia due to lack of association with infection. |
Rash | Telaprevir Boceprevir Simeprevir Faldaprevir |
Preventative skin care and hydration Topical corticosteroids Topical anti-histamine Oral anti-histamines DAA withdrawal |
Severe rash (>50 % of body surface area or systemic symptoms) requires DAA withdrawal and progression warrants discontinuation of all medications. |
Anorectal discomfort | Telaprevir | Diet modification (increased fat intake) Barrier creams Sitz baths Topical corticosteroids Topical lidocaine |
Diarrhea may require additional workup and evaluation. |
Dysgeusia | Boceprevir | Hydration Candies or lozenges Using plastic utensils |
|
Depression | Interferon | Patient selection Support groups and services Anti-depressants |
Monitoring for suicidality is essential while on interferon based therapies for at-risk patients. |
DAA Direct acting antiviral